-1 	|BT| (S (NP (NN Notch-1) (NN Notch-4) (JJ potent) (NN breast) (NN oncogene)) (VP (VBN overexpressed) (NP (JJ triple-negative) (NNS subtypes) (NN breast) (NN cancer)))) |ET| |BS|9:G05.360.340.024.340.375.500 10:A01.236|ES| 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1 27:1
-1 	|BT| (S (NP (NP (ADVP (RB Surprisingly)) (, ,) (VBN given) (VBN proposed) (NN role) (NN loss) (NN function) (NN mutation) (NN p53) (NN gene) (NN development)) (NP (JJ human) (JJ colorectal) (NN cancer)) (, ,)) (VP (VBD found) (NP (NP (NN evidence)) (PP (CC either) (NP (NP (NN increase) (NN rate) (NN adenoma) (NN formation) (NN APC)) (CC +) (: /) (: -) (, ,) (NP (NN p53) (: -)) (: /) (FRAG (: -) (NP (NP (NN animal)) (, ,) (NP (NP (VBD increased) (NN rate) (NN progression) (NN malignancy)) (VP (VBN compared) (NP (NP (NN APC)) (NP (CC +) (: /) (: -) (NN p53) (CC +) (FRAG (: /) (CC +) (NP (NN mouse)))))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495|ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1
-1 	|BT| (S (NP (NNS Tumors)) (VP (VBD graded) (NP (NP (NN histology) (JJ immunostained) (NN p53)) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli)) (, ,) (NP (NN beta-catenin)) (, ,) (NP (NP (NP (NN cyclooxygenase-2) (-LRB- -LRB-) (NN Cox-2) (-RRB- -RRB-) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN iNOS)) (-RRB- -RRB-))) (VBN sequenced) (NN p53) (NN mutation))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 8:C04 18:G05.365.590 21:G05.360.340.024.340.375.249.050 22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 28:H01.158.100.656|ES| 2:1 10:1 12:1 14:1 19:1 34:1 53:1 54:1 55:1 56:1 57:1 58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1
-1 	|BT| (S (NP (DT A) (NN TRAMP/COX) (CD -2) (JJ knockout) (NN mouse) (NN model)) (ADVP (RB also)) (VP (VBD generated) (VP (VB determine) (NP (NN effect) (NN loss) (NN COX-2) (NN gene) (NN prostate) (NN tumorigenesis) (NN TRAMP) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 34:A05.360.444.575|ES| 5:1 9:1 19:1 32:1 52:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1
-1 	|BT| (NP (NP (JJ Aberrant) (NN methylation) (NN SPARC) (NN gene) (NN promoter) (JJ clinical) (NN implication) (JJ gastric) (NN cancer))) |ET| |BS|35:G02.111.570.080.689.675 36:G02.111.087.029.538 37:D12.776.157.125.715|ES| 9:1 18:1 19:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1
-1 	|BT| (NP (NP (NP (NN Activation) (JJ p53-dependent) (NN apoptosis) (JJ acute) (NN ablation) (NN glycogen) (NN synthase) (NN kinase-3beta)) (NP (JJ colorectal) (NN cancer) (NN cell)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11|ES| 17:1 18:1 19:1 66:1 87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1
-1 	|BT| (S (NP (JJ Aldo-keto) (NN reductase) (NN family) (CD 1) (NN B10) (NN gene) (NN silencing)) (VP (VBP result) (NP (NP (NN growth) (NN inhibition) (JJ colorectal) (NN cancer) (NN cell)) (: :) (NP (NP (NN Implication) (NN cancer)) (NN intervention))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 42:G05.355.315.203.374 43:F01.145.544 44:F01.829.263 45:G07.700.320.249|ES| 9:1 17:1 18:1 19:1 94:1 95:1 96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1
-1 	|BT| (FRAG (SBAR (IN Although) (S (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (ADVP (RB morphologically)) (VP (VBZ resembles) (NP (NP (NN colon)) (, ,) (NP (NN CDX2) (NN expression))) (NP (ADJP (RB apparently) (JJR lower)) (JJ normal) (NN colon)))))) |ET| |BS|46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589|ES| 2:1 19:1 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1
-1 	|BT| (S (NP (NN Analysis) (JJ colorectal) (NN cancer) (NN patient) (NN cohort)) (VP (VBZ establishes) (SBAR (S (NP (NN HNF4alpha)) (ADVP (RB significantly)) (VP (VBD upregulated) (NP (VBN compared) (NP (JJ adjacent) (JJ normal) (JJ epithelial) (NN resection)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 49:E05.318.760.500.750 50:M01.643|ES| 17:1 18:1 19:1 50:1 118:1 119:1 120:1 121:1 122:1 123:1 124:1 125:1 126:1 127:1 128:1
-1 	|BT| (S (NP (NN Animal) (NN breast) (NN colon) (NN tumor) (NN therapy) (NN study)) (VP (VBD showed) (SBAR (S (NP (JJ 15-PGDH) (NN gene) (NN therapy)) (VP (VBD produced) (NP (JJ significant) (NN delay) (NN 2LMP) (NN LS174T) (NN tumor) (NN growth))))))) |ET| |BS|8:C04 10:A01.236 19:B01.050 45:G07.700.320.249 51:C04.588.274.476.411.307.180 52:E02|ES| 7:1 9:1 19:1 23:1 102:1 113:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1
-1 	|BT| (S (NP (NN Antagonism) (NN miR-221) (NN miR-222)) (VP (VBZ reduces) (NP (NN growth) (NN colon) (NN tumor) (NN mouse) (NN colitis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 51:C04.588.274.476.411.307.180 53:C06.405.205.265|ES| 7:1 19:1 52:1 102:1 113:1 139:1 140:1 141:1 142:1 143:1
-1 	|BT| (S (NP (NP (JJ Antisense) (NNS oligodeoxynucleotides) (JJ human) (NN superoxide) (NN dismutase) (CD 2)) (CC and/or) (NP (JJ ectopic) (NN bcl-2) (NN overexpression))) (VP (VBD avoided) (NP (NP (NNS polyphenols)) (SBAR (S (NP (JJ chemoradiotherapy-induced) (JJ colorectal) (NN cancer) (NN elimination)) (VP (VBD showed) (NP (NP (JJ mangano-type) (NN superoxide) (NN dismutase) (NN Bcl-2) (JJ key) (NN target) (JJ molecular) (NN mechanism)) (VP (VBN activated) (NP (JJ combined) (NN application) (NN t-PTER) (NNP QUER)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 57:D13.695.578.424.450 58:D08.811.682.881 59:E02.186.079|ES| 17:1 18:1 19:1 36:1 132:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1
-1 	|BT| (FRAG (PP (IN As) (NP (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (VP (VBN associated) (NP (NP (JJR higher) (NN risk) (JJ gastric) (NN cancer)) (, ,) (NP (JJR lower) (NN CDX2) (NN expression)) (VP (VBD compared) (NP (NP (JJ complete) (JJ intestinal) (NN metaplasia) (JJ normal) (NN colon) (NN epithelium)) (VP (VBN resolved) (NP (NP (JJ current) (NN contradiction) (JJ tumor-suppressive) (NN role)) (NN CDX2) (NN colon) (JJ high) (NN prevalence) (NN CDX2) (JJ intestinal) (NN metaplasia)))))))))) |ET| |BS|8:C04 15:F01.829.316.616 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589 60:E05.318.308.985.525.750 61:E05.318.740.600.800 62:A10.272|ES| 2:1 18:1 19:1 31:1 50:1 86:1 108:1 109:1 110:1 113:1 114:1 115:1 117:1 118:1 168:1 169:1 170:1 171:1 172:1 173:1 174:1 175:1 176:1 177:1 178:1 179:1
-1 	|BT| (S (PP (IN As) (NP (JJ key) (NN molecule) (NN drive) (NN progression) (NN chemoresistance) (JJ gastrointestinal) (NN cancer))) (, ,) (NP (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN HER2)) (VP (VBP become) (NP (JJ efficacious) (NN drug) (NN target) (NN setting)))) |ET| |BS|16:C23.550.291.656 63:G05.360.340.024.340.375.500.791.295.305 64:D08.811.913.696.620.682.725.400.009.300 65:D08.811.913.696.620.682.725.400.009.400 66:F01.658.293 67:D26|ES| 2:1 10:1 14:1 18:1 19:1 48:1 102:1 159:1 160:1 168:1 180:1 181:1 182:1 183:1 184:1 185:1 186:1 187:1 188:1 189:1 190:1 191:1 192:1
-1 	|BT| (S (NP (NP (NP (NN Beta-catenin/T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN Tcf)) (-RRB- -RRB-))) (NN signaling)) (NP (RB constitutively) (JJ active) (NN majority) (JJ human) (JJ colorectal) (NN cancer)) (, ,) (VP (VBG accompanying) (NP (NN change) (NN Bcl-2) (NN expression)))) |ET| |BS|4:C04.588.274.476.411.307 23:D12.776.091.249 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 68:A11.118.637.555.567.569 69:G02.111.087.800|ES| 2:1 10:1 14:1 17:1 18:1 19:1 36:1 115:1 158:1 185:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1
-1 	|BT| (S (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD decreased) (NP (NP (JJ human) (JJ gastric) (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN dysplasia) (NN cancer))))) |ET| |BS|47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 114:1 115:1 201:1 202:1 203:1
-1 	|BT| (S (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD decreased) (NP (NP (JJ human) (JJ gastric) (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN dysplasia) (NN cancer))))) |ET| |BS|33:C04.697.098 47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 114:1 115:1 159:1 201:1 202:1 203:1 204:1 205:1 206:1 207:1
-1 	|BT| (S (NP (NN CDX2) (NN expression)) (VP (ADVP (RB significantly)) (VBD decreased) (NP (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (, ,) (NP (VBP express) (NP (NP (JJ gastric) (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC5AC) (NN MUC6)) (-RRB- -RRB-))) (JJ intestinal) (NP (NP (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC2)) (-RRB- -RRB-)))) (, ,)) (VP (VBD compared) (NP (JJ complete) (JJ intestinal) (NN metaplasia))) (, ,) (S (VP (VBP express) (NP (NP (JJ intestinal) (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC2)) (-RRB- -RRB-))))))) |ET| |BS|47:A03.556.124 48:C23.550.589 71:D12.776.395.560.631 72:D12.776.395.560.631.100|ES| 2:1 10:1 14:1 19:1 50:1 86:1 108:1 109:1 110:1 114:1 115:1 124:1 172:1 202:1 208:1 209:1 210:1 211:1 212:1
-1 	|BT| (S (S (NP (NN Cdx2)) (VP (VBZ induces) (NP (NN differentiation) (JJ intestinal) (JJ epithelial) (NN cell) (NN vitro)))) (: ;) (S (ADVP (RB therefore)) (, ,) (VP (VBD sought) (VP (VB establish) (SBAR (IN whether) (S (NP (JJ causal) (NN relationship)) (VP (VBZ exists) (NP (NN Cdx2) (NN activation) (JJ intestinal) (NN metaplasia))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 48:C23.550.589 73:N05.715.350.200 74:G04.299.151 75:A11.436|ES| 2:1 19:1 94:1 109:1 110:1 127:1 213:1 214:1 215:1 216:1 217:1 218:1 219:1 220:1 221:1 222:1 223:1 224:1 225:1
-1 	|BT| (NP (NP (NP (NN CDX2)) (, ,) (NP (NP (JJ human) (NN homologue)) (NP (FW Drosophila) (FW caudal))) (, ,)) (NP (VBN mutated) (NN allele) (NN replication) (NN error) (JJ positive) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 76:B01.050.500.131.617.289.310.250 77:G05.360.340.024.340.030 78:G02.111.087.222|ES| 2:1 17:1 18:1 19:1 36:1 114:1 226:1 227:1 228:1 229:1 230:1 231:1 232:1 233:1
-1 	|BT| (S (NP (NP (NN CDX2)) (, ,) (NP (NN master) (NN regulator) (JJ intestinal) (NN phenotype)) (, ,)) (VP (VBN shown) (NP (NN play) (JJ tumor-suppressive) (NN role) (NN colon) (NN cancer)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 51:C04.588.274.476.411.307.180 79:I03.450.642.693 80:G05.695|ES| 2:1 18:1 19:1 31:1 109:1 113:1 114:1 177:1 234:1 235:1 236:1 237:1 238:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (NP (NP (JJ Gastric) (NN expression) (NN Cdx2)) (ADJP (RB alone) (JJ sufficient))) (VP (VBP induce) (NP (JJ intestinal) (NN metaplasia) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 48:C23.550.589 70:A03.556.875.875|ES| 19:1 52:1 104:1 109:1 110:1 115:1 213:1 239:1 240:1 241:1 242:1 243:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (PP (IN In) (NP (JJ human) (NN CRC) (NN cell))) (, ,) (NP (NN miR-221) (NN miR-222)) (VP (VBP act) (NP (JJ positive) (NN feedback) (NN loop) (NN increase) (NN expression) (NN level) (NN RelA) (NN STAT3)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 82:D12.644.360.024.342.300 83:L01.143.283.425|ES| 2:1 19:1 36:1 40:1 94:1 104:1 115:1 140:1 141:1 233:1 239:1 244:1 245:1 246:1 247:1 248:1 249:1 250:1 251:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (UCP (PP (IN In) (NP (NN mouse))) (, ,) (NP (NP (NN fucosylation) (NN deficiency) (NN lead) (NN colitis) (NN adenocarcinoma)) (, ,) (NP (NN loss) (NN Notch) (NN activation)) (, ,) (NP (NN down-regulation) (NN Hes1))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 53:C06.405.205.265 84:C04.557.470.200.025 85:G02.111.087.225 86:D01.268.556.435 87:C18.654.521|ES| 2:1 19:1 32:1 52:1 104:1 143:1 225:1 239:1 244:1 252:1 253:1 254:1 255:1 256:1 257:1 258:1
-1 	|BT| (S (NP (JJ Correlated) (NN pattern)) (VP (VBN observed) (NP (NP (NN HNF4alpha) (NN Cdx2) (JJ several) (JJ experimental) (NN model) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line)) (: :) (NP (NP (NN xenograft) (JJ nude) (NN mouse)) (, ,) (NP (NN wound) (NN healing) (NN glucose) (NN starvation)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 89:G16.100.856.891 90:C18.654.521.750 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 94:A11.251.210 95:E05.599|ES| 2:1 18:1 19:1 36:1 52:1 72:1 94:1 104:1 113:1 123:1 213:1 259:1 260:1 261:1 262:1 263:1 264:1 265:1 266:1 267:1 268:1 269:1 270:1
-1 	|BT| (S (S (NP (NN CRC) (NN patient)) (VP (VBD decreased) (NP (NN level) (NN miR-195-5p) (NN tumor) (NN tissue))) (S (ADVP (RB significantly)) (VP (VBD shortened) (SBAR (S (NP (NN survival)) (VP (VBD revealed) (NP (NP (NP (NN TCGA) (NN colon) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NN COAD)) (-RRB- -RRB-))) (NN dataset) (NN CRC) (NN cohort))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 46:A03.556.124.526.356 50:M01.643 84:C04.557.470.200.025 96:I03.784 97:V02.302 98:A10|ES| 7:1 10:1 14:1 19:1 113:1 120:1 121:1 124:1 202:1 245:1 249:1 255:1 271:1 272:1 273:1 274:1 275:1 276:1 277:1 278:1
-1 	|BT| (S (S (VP (VBG Crossing) (NP (NP (NP (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Delta14)) (: /) (CC +) (-RRB- -RRB-))) (NP (NP (NN mouse) (JJ prone) (JJ spontaneous) (JJ intestinal) (NN tumor) (NN development) (NN pCdx2-9LacZ)) (NP (JJ transgenic) (NN mouse) (S (VP (VBG containing) (NP (NN LacZ) (NN reporter) (NN control) (JJ 9.3-kb) (NN Cdx2) (NN promoter))))))))) (VP (VBD showed) (SBAR (S (NP (NN promoter) (NN segment)) (VP (VBZ contains) (NP (NP (NN sequence)) (VP (VBG recapitulating) (NP (NN decrease) (NN Cdx2) (NN expression) (JJ intestinal) (NN cancer))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 26:G02.111.570.080 99:B01.050.050.136.500 100:G05.360.340.024.686.545 101:C04.588.274.476.411 102:C04.588.274.476.411 103:G11.427.695.525|ES| 7:1 10:1 14:1 18:1 19:1 35:1 52:1 83:1 109:1 115:1 132:1 213:1 279:1 280:1 281:1 282:1 283:1 284:1 285:1 286:1 287:1 288:1 289:1 290:1 291:1 292:1 293:1 294:1 295:1
-1 	|BT| (S (NP (NN Downregulation) (NN miR-610)) (VP (VBZ promotes) (SBAR (S (NP (NN proliferation) (NN tumorigenicity)) (VP (VBZ activates) (NP (NN Wnt/beta-catenin) (NN signaling) (JJ human) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 105:G02.149.115.800.925|ES| 19:1 36:1 195:1 296:1 297:1 298:1 299:1 300:1 301:1 302:1 303:1 304:1
-1 	|BT| (S (NP (JJ Ectopic) (NN expression) (NN miR-139-5p) (NN colon) (NN cancer) (NN cell) (NN line)) (VP (ADVP (RB significantly)) (NP (VBD suppressed) (NP (NP (NN cell) (NN growth) (VBN evidenced) (NN cell) (NN viability) (NN assay)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.001)))) (-RRB- -RRB-))) (NP (NP (NP (NN colony) (NN formation) (NN assay)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))) (NP (NP (NN xenograft) (NN tumor) (NN growth) (JJ nude) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))))))) |ET| |BS|8:C04 20:G03.495 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 94:A11.251.210 106:E05.091 107:G05.355.315.202 108:G04.299.316 109:I01.696.116|ES| 7:1 10:1 14:1 18:1 19:1 43:1 52:1 94:1 102:1 113:1 115:1 124:1 264:1 265:1 266:1 305:1 306:1 307:1 308:1 309:1 310:1 311:1 312:1 313:1 314:1 315:1
-1 	|BT| (NP (NP (NN Expression) (JJ gut-enriched) (JJ Kruppel-like) (NN factor)) (FRAG (-LRB- -LRB-) (NP (NP (JJ Kruppel-like) (NN factor) (CD 4) (-RRB- -RRB-) (NN gene)) (JJ human) (ADJP (NN colon) (NN cancer) (NN cell) (NN line) (NN RKO) (JJ dependent)) (NN CDX2)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210|ES| 9:1 10:1 14:1 18:1 19:1 36:1 94:1 113:1 114:1 185:1 264:1 316:1 317:1 318:1 319:1 320:1 321:1
-1 	|BT| (S (NP (NN Expression) (NN KLK13) (NN KLK14) (NN gene)) (VP (VBN examined) (NP (NP (NN mRNA) (NN protein) (NN level) (NN cohort) (CD 57) (NN patient)) (NP (NP (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 110:C04.588.894.797.520.109.220.249 111:D13.444.735.544 112:D12.776.097.820|ES| 4:1 9:1 10:1 14:1 18:1 19:1 120:1 121:1 249:1 316:1 322:1 323:1 324:1 325:1 326:1 327:1 328:1 329:1
-1 	|BT| (S (NP (JJ Further) (NN decrease) (NN CDX2) (NN expression) (JJ gastric) (NN dysplasia) (NN cancer)) (VP (VBZ suggests) (NP (NP (NN CDX2) (NN play) (JJ similar) (JJ anticarcinogenic) (NN role)) (JJ intestinal) (NN metaplasia) (NN colon)))) |ET| |BS|15:F01.829.316.616 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589 70:A03.556.875.875 79:I03.450.642.693|ES| 18:1 19:1 31:1 86:1 109:1 110:1 113:1 114:1 115:1 203:1 238:1 295:1 330:1 331:1 332:1 333:1
-1 	|BT| (FRAG (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ high) (NN uniform) (NN expression) (NN CDX2)) (NP (NP (JJ characteristic) (JJ metastatic) (JJ colorectal) (NN cancer)) (, ,) (NP (ADJP (ADJP (JJ weak)) (CC and/or) (ADJP (JJ focal))) (NN CDX2) (NN expression) (JJ alert) (JJ surgical) (NN pathologist) (NN possibility) (JJ primary) (NN lung) (NN adenocarcinoma)) (, ,) (NP (ADVP (RB especially)) (NN presence) (NN goblet) (NN cell) (NN morphology))))) |ET| |BS|113:C04.697.650 114:J01.637.215 115:E04|ES| 2:1 17:1 18:1 19:1 94:1 114:1 115:1 149:1 178:1 255:1 328:1 334:1 335:1 336:1 337:1 338:1 339:1 340:1 341:1 342:1 343:1 344:1 345:1 346:1 347:1 348:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN Cdx2)) (VP (VBD decreased) (S (VP (VBG knocking) (NP (NN HNF4alpha) (JJ human) (NN colon) (NN cancer) (NN cell)) (S (VP (VBG using) (NP (NN siRNA) (NN colon) (NN mouse))))))) (S (ADVP (RB conditionally)) (VP (VBD knocked) (NP (NN Hnf4alpha) (NN gene) (JJ adult) (NN intestine)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN Hnf4alpha)) (PRN (-LRB- -LRB-) (NP (NN f/f)) (-RRB- -RRB-))) (: ;) (NP (NNP VilCre) (-LRB- -LRB-) (NN ERT2) (-RRB- -RRB-) (NN mouse))) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 41:A11 46:A03.556.124.526.356 47:A03.556.124 55:B01.050.150.900.649.801.400.112.400.400 116:D08.811.913.696.620.682.700.567.249.750 117:D13.150.650.700 118:D01.248.497.158.380 119:M01.060.116|ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 52:1 94:1 113:1 123:1 202:1 213:1 217:1 334:1 349:1 350:1 351:1 352:1 353:1 354:1 355:1 356:1 357:1 358:1 359:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ stable) (NN overexpression)) (VP (VBG using) (NP (JJ lentiviral) (NN vector) (NN NCI-H460) (NN A549) (NN cell)))) (VP (VBD inhibited) (NP (NN tumor) (NN xenograft) (NN growth) (JJ immunodeficient) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (ADJP (CD 50) (NN %)) (NN reduction)) (VP (VBN compared) (NP (NN control)) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))) (, ,) (PP (IN whereas) (NP (NP (NP (NN effect) (NN mir-660) (NN overexpression) (JJ absent) (NN H1299)) (, ,) (NP (NP (NN lung) (NN cancer) (NN cell) (NN line)) (VP (VBG lacking) (NP (NN p53) (NN locus))))) (, ,) (NP (ADJP (FW vitro) (FW vivo)) (NN assay))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 11:B01.050.150.900.649.865.635.505.500 41:A11 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 94:A11.251.210 106:E05.091 120:I01.409.418.750.600.480.150 121:B04.820.650.589 122:C14.280.383 123:G05.360.337 124:C20.673|ES| 2:1 7:1 10:1 12:1 14:1 18:1 19:1 50:1 52:1 75:1 94:1 102:1 152:1 216:1 264:1 265:1 289:1 310:1 328:1 334:1 350:1 360:1 361:1 362:1 363:1 364:1 365:1 366:1 367:1 368:1 369:1 370:1 371:1 372:1 373:1 374:1 375:1 376:1 377:1 378:1
-1 	|BT| (S (NP (NN gamma-Secretase) (NN inhibitor)) (VP (VBP abrogate) (NP (NP (JJ oxaliplatin-induced) (NN activation) (NN Notch-1) (NN signaling) (NN pathway) (NN colon) (NN cancer) (NN cell)) (VP (VBG resulting) (NP (VBN enhanced) (NN chemosensitivity)))))) |ET| |BS|41:A11 69:G02.111.087.800 125:D08.811.277.656.300.032 126:G02.111.087.800|ES| 18:1 19:1 20:1 94:1 113:1 195:1 225:1 379:1 380:1 381:1 382:1 383:1 384:1 385:1 386:1
-1 	|BT| (NP (NP (NP (NN Germline) (JJ somatic) (NN mutation) (NN BER) (NN gene)) (, ,) (NP (NP (NN MutY) (NN Homolog)) (PRN (-LRB- -LRB-) (NP (NN MUTYH/MYH)) (-RRB- -RRB-))) (NP (NP (JJ DNA-directed) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NN POLB)) (-RRB- -RRB-))) (, ,)) (NP (VBN associated) (VBN increased) (NN risk) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 61:E05.318.740.600.800 127:D08.811.913.696.445.308.300 128:E02.095.301 129:G02.111.087.219 130:A05.360.490|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 34:1 47:1 169:1 171:1 387:1 388:1 389:1 390:1 391:1 392:1 393:1 394:1 395:1
-1 	|BT| (S (NP (NN HDAC8) (NN STAT3)) (VP (VBP repress) (NP (NN BMF) (NN gene) (NN activity) (NN colon) (NN cancer) (NN cell)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 41:A11 46:A03.556.124.526.356 82:D12.644.360.024.342.300|ES| 9:1 18:1 19:1 94:1 113:1 251:1 396:1 397:1 398:1 399:1
-1 	|BT| (NP (NP (ADJP (RB Here) (VBN studied)) (NN role) (NN HNF4alpha) (NN mechanism) (NN deregulation) (NN Cdx2) (NN colon) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 18:1 19:1 31:1 113:1 123:1 162:1 213:1 400:1 401:1 402:1
-1 	|BT| (S (NP (ADJP (RB Here) (VBN investigated)) (NP (NN role) (NN Bcl-3) (NN azoxymethane/dextran) (NN sulfate) (NN sodium)) (PRN (-LRB- -LRB-) (NP (NN AOM/DSS)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (NP (NN colon) (NN tumor)) (, ,) (NP (NN mouse) (NN model) (JJ colitis-associated) (JJ colorectal) (NN cancer)) (JJ human)))) |ET| |BS|4:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 51:C04.588.274.476.411.307.180 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 131:D09.698.365.272.300 132:D02.172.080|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 52:1 72:1 113:1 400:1 403:1 404:1 405:1 406:1 407:1 408:1 409:1 410:1
-1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBD investigated) (NP (NP (NN cell) (NN death) (NN signaling) (NN mechanism)) (VP (VBD induced) (NP (NN PGG) (JJ human) (NN prostate) (NN cancer) (NN cell) (JJ different) (NN p53) (JJ functional) (NN status)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 133:D01.248.497.158.685.750.744.600 134:G04.299.139 135:C23.550.260|ES| 2:1 12:1 18:1 19:1 36:1 77:1 94:1 162:1 195:1 400:1 403:1 411:1 412:1 413:1 414:1 415:1 416:1
-1 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (NP (NN report) (ADJP (RB inversely) (JJ related)) (NN expression) (NN miR-137) (NN CAR) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell)) (, ,) (SBAR (WHADVP (WRB wherein)) (S (NP (NN miR-137)) (VP (VBD downregulated) (NP (JJ resistant) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320 139:J01.937.500.100|ES| 2:1 19:1 94:1 115:1 400:1 417:1 418:1 419:1 420:1 421:1 422:1 423:1 424:1 425:1 426:1 427:1
-1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBP show) (SBAR (S (NP (NNP NANOG)) (VP (VBD expressed) (NP (NP (NN NANOG1) (NN NANOGP8) (JJ human) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-)))))))) |ET| |BS|4:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 6:1 10:1 14:1 17:1 18:1 19:1 36:1 245:1 428:1 429:1 430:1 431:1 432:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (JJ molecular) (NN detail)) (VP (VBG underlying) (NP (NP (NN miR-146a) (JJ mediated) (NN regulation) (NN target) (NN gene) (JJ precise) (JJ biological) (NN function) (NN cancer)) (, ,) (NP (NP (RB especially) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) (VP (VBZ remains) (ADJP (JJ unclear)))) |ET| |BS|104:C04.557.470.200.025.255 140:G05.355.315 141:G16.100|ES| 2:1 9:1 10:1 14:1 18:1 19:1 33:1 160:1 161:1 303:1 304:1 345:1 433:1 434:1 435:1 436:1 437:1 438:1 439:1 440:1 441:1 442:1 443:1
-1 	|BT| (NP (NP (NP (NP (JJ Human) (NN CRC) (NN tissue)) (NP (JJR higher) (NN level) (NN miR-221) (NN miR-222) (JJ nontumor) (NN colon) (NN tissue))) (: ;) (NP (NN increase)) (VP (VBD correlated) (NP (VBN increased) (NN level) (NN RelA) (NN STAT3) (NNS mRNAs))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544|ES| 19:1 40:1 47:1 113:1 140:1 141:1 170:1 217:1 245:1 249:1 250:1 251:1 272:1 444:1 445:1 446:1 447:1
-1 	|BT| (S (NP (NN Hypermethylation) (NN miR-137) (NN promoter) (JJ negative) (NN regulation) (NN miR-137) (NN CAR)) (VP (VP (VBP contribute) (NP (NP (NN part)) (VP (VBD reduced) (NP (NN miR-137) (NN expression))))) (VP (VBD increased) (NP (NN CAR) (NN MDR1) (NN expression) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 142:I01.880.604|ES| 19:1 47:1 83:1 94:1 115:1 420:1 421:1 423:1 424:1 438:1 448:1 449:1 450:1 451:1 452:1 453:1
-1 	|BT| (NP (NP (NP (NN Immunohistochemistry) (NN beta-catenin)) (, ,) (NP (NN c-myc)) (, ,) (NP (NP (NN Ki-67) (NN TUNEL-staining)) (VP (VBN performed) (VP (VBP investigate) (NP (NP (NN TQ) (POS 's)) (NN effect) (JJ major) (JJ colorectal) (NN cancer) (NN pathway))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 143:E01.370.225.500.607.512 144:E05.393.475|ES| 2:1 17:1 18:1 19:1 60:1 75:1 383:1 454:1 455:1 456:1 457:1 458:1 459:1 460:1 461:1 462:1
-1 	|BT| (S (PP (IN In) (NP (JJ nude) (NN mouse) (NN xenograft) (NN model))) (, ,) (NP (NN overexpression) (NN miR-141) (NN knockdown) (NN MAP4K4)) (ADVP (RB significantly)) (VP (VBD repressed) (NP (JJ pancreatic) (NN cancer) (NN cell) (NN growth)))) |ET| |BS|41:A11 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875|ES| 2:1 18:1 19:1 52:1 72:1 94:1 102:1 124:1 152:1 244:1 265:1 266:1 463:1 464:1 465:1 466:1 467:1
-1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN PIM) (NN kinase)) (VP (VBP activate) (S (NP (NN MYC) (NN signaling) (NN mRNA) (NN translation) (NN prostate) (NN cancer)) (VP (VBP cooperate) (S (NP (NN MYC)) (VP (VB accelerate) (NP (NN tumorigenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 69:G02.111.087.800 145:G02.111.087.675.871|ES| 2:1 18:1 19:1 77:1 78:1 195:1 244:1 325:1 468:1 469:1 470:1 471:1 472:1 473:1 474:1 475:1
-1 	|BT| (S (PP (IN In) (NP (JJ current) (NN report))) (, ,) (VBN used) (S (NP (NN DLD-1) (JJ colorectal) (NN cancer) (NN cell)) (ADVP (RB stably)) (NP (VBN transfected) (NP (NN POX) (NN gene) (NN control) (JJ tetracycline-inducible) (NN promoter))) (VP (VBD found) (SBAR (S (NP (CD three) (NN pathway) (NN cross) (NN talk)) (VP (VBD downregulated) (NP (NP (NN POX)) (: :) (NP (NP (NP (NP (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NN pathway)) (, ,) (NP (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN pathway) (NN Wnt/beta-catenin) (NN pathway)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 23:D12.776.091.249 24:D08.811.600.720.750 41:A11 64:D08.811.913.696.620.682.725.400.009.300 146:D02.455.426.559.847.562.900.875 147:G02.149.115.800.925 148:G12.425.143.281|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 37:1 61:1 76:1 83:1 94:1 102:1 104:1 175:1 184:1 185:1 186:1 187:1 244:1 289:1 302:1 383:1 417:1 426:1 476:1 477:1 478:1 479:1 480:1 481:1 482:1 483:1 484:1
-1 	|BT| (NP (NP (PP (IN In) (NP (JJ particular))) (, ,) (NP (NP (NN expression) (JJ intestine-specific) (NN transcription) (NN factor) (NN Cdx2)) (, ,) (NP (JJ key) (NN gene) (JJ intestinal) (NN identity)) (VP (VBD downregulated) (NP (NP (JJ invasive) (NN cancer) (NN cell)) (, ,) (VP (VBD reduced) (NP (NN wound) (NN healing) (NN vitro)))))))) |ET| |BS|41:A11 47:A03.556.124 89:G16.100.856.891 149:G05.360.340.024.340.364.875.890|ES| 2:1 9:1 18:1 19:1 94:1 109:1 115:1 159:1 185:1 213:1 216:1 244:1 267:1 268:1 426:1 452:1 485:1 486:1 487:1 488:1 489:1
-1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NN colon) (NN cancer) (NN cell)) (VP (MD may) (VP (VB up-regulate) (NP (NN Notch-1) (JJ protective) (NN mechanism) (NN response) (NN chemotherapy))))) |ET| |BS|41:A11 150:Z01.542.248.960 151:E02.319|ES| 2:1 18:1 19:1 20:1 94:1 113:1 162:1 244:1 490:1 491:1 492:1 493:1 494:1 495:1
-1 	|BT| (FRAG (PP (IN In) (NP (JJ adult))) (, ,) (NP (NP (JJ Cdx1) (NN Cdx2)) (, ,) (NP (NN Cdx4)) (, ,) (NP (ADJP (RB intensively) (VBN explored)) (NN function) (JJ intestinal) (NN tissue) (NN homeostasis) (NN pathogenesis) (JJ gastrointestinal) (NN cancer)))) |ET| |BS|47:A03.556.124 98:A10 119:M01.060.116 152:G07.700.345|ES| 2:1 18:1 19:1 33:1 109:1 183:1 213:1 244:1 272:1 355:1 496:1 497:1 498:1 499:1 500:1 501:1
-1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBP demonstrate) (S (NP (NP (NP (NN histone) (NN deacetylase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN HDACi)) (-RRB- -RRB-))) (NN vorinostat) (NN LBH589)) (VP (ADVP (RB significantly)) (VBP downregulate) (NP (NN TS) (NN gene) (NN expression) (NN panel) (NN colon) (NN cancer) (NN cell) (NN line)))))) |ET| |BS|94:A11.251.210 153:D27.505.519.389.360 154:Z01.058.266.887 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 113:1 115:1 124:1 131:1 244:1 264:1 380:1 502:1 503:1 504:1 505:1 506:1 507:1 508:1 509:1 510:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN study))) (, ,) (NP (VBN explored) (NN role) (NN miR-141) (JJ pancreatic) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 2:1 18:1 19:1 31:1 131:1 244:1 463:1 467:1 499:1
-1 	|BT| (FRAG (NP (ADVP (FW In) (FW vitro)) (PRN (, ,) (NP (NP (VBN forced) (NN expression) (NN Cdx2) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line)) (SBAR (S (NP (VBN retarded) (NN wound) (NN repair)) (VP (VBD reduced) (NP (NN migration)))))) (, ,))) (SBAR (IN whereas) (S (NP (NN inhibition) (NN Cdx2) (NN expression) (NN RNA) (NN interference)) (VP (VBD enhanced) (NP (NN migration)))))) |ET| |BS|43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 89:G16.100.856.891 94:A11.251.210 122:C14.280.383 156:G05.355.315.203.374.790|ES| 2:1 18:1 19:1 36:1 94:1 103:1 113:1 115:1 213:1 216:1 244:1 264:1 267:1 372:1 385:1 452:1 511:1 512:1 513:1 514:1 515:1 516:1
-1 	|BT| (NP (NP (NP (NN Incubation) (NN CRC) (NN cell) (NN miR-221) (NN miR-222) (NN inhibitor)) (SBAR (S (NP (VBD reduced) (NN proliferation) (NN colony) (NN formation)) (VP (VBN compared) (NP (NN control) (NN cell))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 41:A11 109:I01.696.116|ES| 19:1 43:1 50:1 94:1 140:1 141:1 245:1 289:1 299:1 314:1 380:1 452:1 517:1
-1 	|BT| (NP (NP (ADVP (RB Interestingly)) (, ,) (NP (NP (NP (JJ gastric) (NN adenocarcinoma)) (ADJP (RB significantly) (JJ frequent)) (NN Pdx-1-Cre)) (: ;) (NP (NN Smad4) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Trp53) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NP (NP (NN Cdh1) (-LRB- -LRB-) (NN F) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (: /) (CC +) (-RRB- -RRB-))) (NN mouse) (NN Pdx-1-Cre)) (: ;) (NP (NN Smad4) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Trp53) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Cdh1) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-)) (NN mouse)) (, ,) (S (NP (VBG demonstrating) (NN Cdh1) (NN heterozygosity)) (VP (VBZ accelerates) (NP (NN development) (NN progression) (JJ gastric) (NN adenocarcinoma)))) (, ,) (NP (NN combination) (NN loss) (NN Smad4) (NN p53))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 70:A03.556.875.875 84:C04.557.470.200.025 118:D01.248.497.158.380 157:G05.380.383|ES| 2:1 10:1 12:1 14:1 19:1 32:1 35:1 48:1 51:1 52:1 86:1 124:1 217:1 255:1 518:1 519:1 520:1 521:1 522:1 523:1 524:1 525:1 526:1 527:1 528:1 529:1 530:1
-1 	|BT| (S (NP (JJ Intestinal) (NN metaplasia) (NN dysplasia) (JJ low) (NN expression) (NN CDX2)) (VP (MD may) (VP (VB serve) (NP (JJ predictive) (NN marker) (JJ gastric) (NN cancer))))) |ET| |BS|47:A03.556.124 48:C23.550.589 158:D23.101|ES| 18:1 19:1 86:1 110:1 114:1 115:1 203:1 204:1 491:1 531:1 532:1 533:1 534:1
-1 	|BT| (NP (NP (NN INTRODUCTION)) (: :) (NP (NP (NP (NP (JJ Triple) (JJ negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN TNBC)) (-RRB- -RRB-))) (NP (JJ aggressive) (ADJP (RB currently) (JJ specific)) (JJ therapeutic) (NN target))) (, ,) (NP (NP (NN hormone) (NN receptor) (JJ human) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN type) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN HER2)) (-RRB- -RRB-)))) (: ;) (ADVP (RB therefore)) (, ,) (NP (NN prognosis) (JJ poor))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 159:I01.880.735.634 160:C04.588.180.788 161:D06.472 162:F01.145.126.125 163:E01.789|ES| 2:1 10:1 14:1 18:1 19:1 23:1 36:1 102:1 104:1 148:1 160:1 184:1 185:1 186:1 188:1 217:1 218:1 449:1 535:1 536:1 537:1 538:1 539:1 540:1 541:1 542:1 543:1 544:1 545:1
-1 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
-1 	|BT| (S (NP (NN LINE-1) (NN methylation)) (VP (VBD decreased) (SBAR (S (NP (NN transition) (JJ intestinal) (NN metaplasia) (JJ gastric) (NN adenoma) (NN decrease)) (VP (VBD occurred) (NP (NN transition) (JJ gastric) (NN adenoma) (NN GC))))))) |ET| |BS|17:C04.557.470.035 36:G02.111.087.029.538 47:A03.556.124 48:C23.550.589 70:A03.556.875.875|ES| 19:1 42:1 81:1 86:1 109:1 110:1 202:1 295:1 551:1 552:1 553:1 554:1
-1 	|BT| (S (NP (NP (ADJP (RB Little) (VBN known)) (JJ biological) (NN significance) (NN ELK1)) (, ,) (NP (JJ transcriptional) (NN factor))) (VP (VBZ activates) (NP (NP (JJ downstream) (NN target)) (PP (VBG including) (NP (NP (NN c-fos) (NN proto-oncogene)) (, ,) (NP (NN bladder) (NN cancer))))))) |ET| |BS|165:G05.360.340.024.340.375.500.791.330 166:D12.776.930 167:H01.158.273|ES| 2:1 18:1 19:1 160:1 185:1 301:1 440:1 555:1 556:1 557:1 558:1 559:1 560:1 561:1 562:1 563:1 564:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (NP (NP (NP (NN CRC) (NN cell) (NN line)) (PRN (-LRB- -LRB-) (NP (NN HCT116) (NN RKO)) (-RRB- -RRB-))) (VP (VBN transfected) (S (NP (NN miR-221) (NN miR-222)) (VP (VBP mimic) (NP (NN inhibitor))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 94:A11.251.210 168:E05.581|ES| 10:1 14:1 19:1 94:1 104:1 140:1 141:1 245:1 264:1 320:1 380:1 479:1 565:1 566:1 567:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (NN Notch) (NN status)) (VP (VBD analysed) (S (VP (VBG studying) (S (NP (NN expression) (NN Notch) (NN effector) (NN Hes1) (NN Notch) (NNS ligands/receptors)) (NP (JJ human) (JJ colorectal) (NP (NP (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NN mouse) (NN model) (NN Apc) (NN mutation)))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 168:E05.581 169:D12.776.543.750.725 170:D27.720.470.480|ES| 10:1 14:1 17:1 18:1 19:1 34:1 36:1 52:1 72:1 104:1 115:1 245:1 256:1 258:1 280:1 416:1 565:1 568:1 569:1 570:1 571:1
-1 	|BT| (NP (NP (NN Methylation) (NN rate) (NN SPARC) (NN gene)) (NP (NP (CD 80) (NN %)) (NP (CD ten) (JJ gastric) (NN cancer) (NN cell) (NN line)) (NP (NP (CD 74) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 163) (CD 220)) (-RRB- -RRB-))) (NP (JJ primary) (NN tumor))) (, ,) (NP (NP (ADJP (CD 5) (NN %)) (JJ normal) (JJ gastric) (NN mucosa)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 40)))) (-RRB- -RRB-)))) |ET| |BS|8:C04 36:G02.111.087.029.538 37:D12.776.157.125.715 94:A11.251.210 171:E05.318.308.985.775.500 172:A03.556.875.875.440 173:C07.465.864.500|ES| 2:1 7:1 9:1 10:1 14:1 18:1 19:1 41:1 82:1 86:1 94:1 118:1 264:1 344:1 369:1 572:1 573:1 574:1 575:1 576:1 577:1 578:1 579:1 580:1 581:1 582:1
-1 	|BT| (FRAG (NP (S (NP (NP (NNS Mice) (NN mutation) (NN mismatch) (NN repair) (NN gene)) (, ,) (NP (NN Msh2) (NN Mlh1)) (, ,)) (VP (VBP exhibit) (S (NP (NN mismatch) (NN repair) (NN defect)) (VP (VBN predisposed) (S (VP (VBG developing) (NP (JJ gastrointestinal) (NN cancer)))))))) (, ,) (NN lymphoma) (NN tumor) (NN organ) (NN system))) |ET| |BS|6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 174:G02.111.087.219.220 175:J01.897.280.500.269 176:C04.557.386|ES| 2:1 7:1 9:1 18:1 19:1 34:1 183:1 513:1 583:1 584:1 585:1 586:1 587:1 588:1 589:1 590:1 591:1 592:1 593:1
-1 	|BT| (S (S (NP (NN miR-137) (NN overexpression)) (VP (VBD resulted) (NP (NP (NN downregulation) (NN CAR) (NN protein) (NN mRNA)) (PRN (-LRB- -LRB-) (PP (IN via) (NP (NN mRNA) (NN degradation))) (-RRB- -RRB-))))) (: ;) (S (VBN sensitized) (NP (JJ doxorubicin-resistant) (NN cell) (NN doxorubicin)) (-LRB- -LRB-) (VP (VP (VBN shown) (S (VP (VBN reduced) (NP (NN proliferation))))) (, ,) (VP (VBD increased) (NP (NN apoptosis))) (VP (VBD increased) (NP (JJ G2-phase) (NN cell) (NN cycle) (NN arrest))) (SINV (-RRB- -RRB-) (NP (VBD reduced) (FW vivo) (NN growth) (NN rate) (NN neuroblastoma) (NN xenograft)))))) |ET| |BS|7:D12.776 39:G04.299.139.160 41:A11 45:G07.700.320.249 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 111:D13.444.735.544 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 177:G04.299.134.109.500 178:G02.111.780|ES| 2:1 4:1 10:1 14:1 19:1 41:1 47:1 89:1 94:1 102:1 152:1 217:1 237:1 265:1 299:1 325:1 378:1 420:1 421:1 423:1 424:1 452:1 594:1 595:1 596:1 597:1 598:1 599:1 600:1 601:1 602:1
-1 	|BT| (S (NP (NN miR-137)) (VP (VBZ regulates) (SBAR (S (NP (JJ constitutive) (NN androstane) (NN receptor)) (VP (VBZ modulates) (NP (NN doxorubicin) (NN sensitivity) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320|ES| 19:1 94:1 186:1 420:1 422:1 423:1 424:1 599:1 603:1 604:1 605:1 606:1 607:1
-1 	|BT| (S (NP (NN miR-490-3p)) (VP (VBD exhibited) (NP (NP (JJ progressive) (NN downregulation) (NN gastritis)) (, ,) (NP (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN adenocarcinoma) (NN H))))) |ET| |BS|47:A03.556.124 48:C23.550.589 84:C04.557.470.200.025 85:G02.111.087.225 175:J01.897.280.500.269 179:D01.248.497.300.459.700 180:C06.405.205.697|ES| 2:1 19:1 109:1 110:1 255:1 595:1 608:1 609:1 610:1 611:1 612:1
-1 	|BT| (S (NP (NN Mir-660)) (VP (VBD downregulated) (SBAR (S (NP (NN lung) (NN cancer) (NN patient) (NN replacement)) (VP (VBZ inhibits) (NP (NP (NN lung) (NN tumorigenesis)) (VP (VBG targeting) (NP (NN MDM2-p53) (NN interaction))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 32:C04.697.098.500 33:C04.697.098 50:M01.643 122:C14.280.383 181:E04.936.494 182:A04.411|ES| 18:1 19:1 78:1 120:1 328:1 426:1 613:1 614:1 615:1 616:1 617:1 618:1
-1 	|BT| (S (NP (NP (NN miRNA-141)) (, ,) (VP (VBD downregulated) (NP (JJ pancreatic) (NN cancer))) (, ,)) (VP (VBZ inhibits) (NP (NN cell) (NN proliferation) (NN invasion)) (S (VP (ADVP (RB directly)) (VBG targeting) (NP (NN MAP4K4)))))) |ET| |BS|122:C14.280.383 183:G04.299.233.750 184:D13.150.650.319|ES| 2:1 18:1 19:1 94:1 299:1 426:1 465:1 467:1 615:1 616:1 619:1 620:1 621:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (VP (VBD identified) (SBAR (S (NP (NN Usp28) (NN c-MYC) (NN target) (NN gene)) (ADVP (RB highly)) (VBD expressed) (NP (JJ murine) (JJ human) (JJ intestinal) (NN cancer)) (, ,) (VP (VBZ indicates) (SBAR (S (NP (NN USP28) (NN c-MYC) (NN form) (JJ positive) (NN feedback) (NN loop)) (VP (VBZ maintains) (NP (JJ high) (NN c-MYC) (NN protein) (NN level) (NN tumor)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 83:L01.143.283.425 101:C04.588.274.476.411 185:G05.360.340.024.340.375.500.791.420 186:G05.360.340.024.340.375.500.791.420 187:D08.622.705 188:N02.628 189:V02.460|ES| 2:1 4:1 6:1 7:1 9:1 18:1 19:1 36:1 109:1 160:1 178:1 233:1 247:1 248:1 249:1 622:1 623:1 624:1 625:1 626:1 627:1 628:1 629:1 630:1 631:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (JJ gastric) (NN cancer) (JJ human)) (ADVP (RB often)) (VP (VBD preceded) (NP (NP (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN phenotype))) (S (VP (VBD described) (SBAR (S (ADVP (RB strongly)) (VP (VBZ suggests) (NP (NP (NN involvement) (NN Cdx2) (NN initiation) (NN process)) (VBG leading) (JJ intestinal) (NN neoplasia) (JJ gastric) (NN mucosa))))))))) |ET| |BS|47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 86:D01.268.556.435 190:C04.588.274.476.767 191:A03.556.124.369|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 213:1 236:1 331:1 579:1 622:1 632:1 633:1 634:1 635:1 636:1 637:1 638:1 639:1 640:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD reduced) (NP (JJ gastric) (NN dysplasia) (NN cancer)))) |ET| |BS|70:A03.556.875.875|ES| 2:1 18:1 19:1 86:1 114:1 115:1 201:1 203:1 452:1 622:1
-1 	|BT| (S (NP (NP (NN Mutation) (NN Pla2g2a)) (, ,) (NP (JJ secretory) (NN phospholipase) (NN A) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (NP (NN gene)) (, ,)) (VP (VP (ADVP (RB dramatically)) (VB increase) (NP (NN number) (JJ intestinal) (NN polyp)) (VP (VB develop) (NP (NP (NP (JJ multiple) (JJ intestinal) (NN neoplasia)) (PRN (-LRB- -LRB-) (NP (NN Min)) (-RRB- -RRB-))) (NN mouse)))) (, ,) (NP (JJ murine) (ADJP (NN model) (JJ adenomatous) (NN polyposis) (NN coli) (JJ human))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 102:C04.588.274.476.411 192:D08.811.277.352.100.680.750.937.750 193:C23.300.825.411|ES| 2:1 9:1 10:1 14:1 19:1 36:1 40:1 52:1 57:1 58:1 59:1 69:1 72:1 109:1 148:1 627:1 640:1 641:1 642:1 643:1 644:1 645:1 646:1 647:1 648:1 649:1 650:1
-1 	|BT| (S (NP (NN Notch1)) (ADVP (RB directly)) (VP (VBD induced) (NP (NN CD133) (NN expression) (JJ human) (JJ diffuse) (NN type) (JJ gastric) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 36:1 86:1 115:1 412:1 543:1 621:1 651:1 652:1 653:1
-1 	|BT| (S (NP (NP (CD One) (JJ common) (JJ rate-limiting) (NN mutation)) (JJ human) (NN CRC)) (VP (VBZ occurs) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 194:G05.355.044.250.750|ES| 9:1 10:1 11:1 14:1 19:1 34:1 36:1 57:1 58:1 59:1 245:1 654:1 655:1 656:1 657:1
-1 	|BT| (S (NP (PRP$ Our) (NP (NP (JJ recent) (JJ global) (NN analysis) (NN CpG) (NN island) (NN hypermethylation) (NN gene) (NN expression) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NN cell) (NN line)) (VP (VBD revealed) (S (NP (NN SOX17) (NN gene) (NN silencing)) (NP (VBN associated) (NN DNA) (NN hypermethylation) (NN CpG) (NN island) (NN promoter) (NN region))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 42:G05.355.315.203.374 94:A11.251.210 155:G05.355.310 195:G02.111.570.080.380.160 196:G02.111.570.080.689.675 197:A01.456.505.420 198:D13.444.308|ES| 9:1 10:1 14:1 17:1 18:1 19:1 83:1 94:1 100:1 115:1 169:1 245:1 264:1 275:1 658:1 659:1 660:1 661:1 662:1 663:1 664:1 665:1 666:1 667:1
-1 	|BT| (NP (NP (NP (NN Overexpression) (NN miR-141) (JJ pancreatic) (NN cancer) (NN cell)) (VBD inhibited) (NP (NN cell) (NN proliferation)) (, ,) (NP (NP (NN clonogenicity)) (, ,) (NP (NN invasion)) (: ;) (NP (VBN induced) (NN G1) (NN arrest) (NN apoptosis)) (: ;) (NP (VBN enhanced) (NN chemosensitivity))))) |ET| |BS|39:G04.299.139.160 41:A11 122:C14.280.383 183:G04.299.233.750|ES| 2:1 18:1 19:1 89:1 94:1 217:1 299:1 365:1 385:1 386:1 412:1 463:1 467:1 602:1 620:1 668:1 669:1 670:1
1 	|BT| (S (NP (JJ Genetic) (NN analysis) (NN C/EBPalpha) (NN gene) (NN progress)) (VP (ADVP (RB fully)) (VB evaluate) (NP (ADJP (NN role) (JJ novel)) (NN tumor) (NN suppressor) (NN lung) (NN cancer)))) |ET| |BS|15:F01.829.316.616 206:G05.360.340.024.340.375.249 225:E05.337 259:D12.776.395.240.150.500 260:E01.370.225.562|ES| 7:1 9:1 18:1 19:1 31:1 328:1 661:1 700:1 886:1 887:1 888:1 889:1 890:1 891:1
1 	|BT| (S (NP (JJ Preneoplastic) (JJ neoplastic) (NNS hepatocytes)) (VP (VBP undergo) (NP (NN c-Myc) (NN up-regulation) (NN overgrowth) (NN rat)) (NP (NP (RB genetically) (JJ susceptible) (NN hepatocarcinogenesis)) (, ,) (NP (JJ resistant) (NN rat))))) |ET| |BS|8:C04 142:I01.880.604 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 261:C23.550.291.687.500 262:A11.436.348|ES| 2:1 19:1 427:1 824:1 849:1 892:1 893:1 894:1 895:1 896:1 897:1 898:1 899:1 900:1
1 	|BT| (NP (NP (NP (DT The) (NN HER2/neu) (NN oncogene) (JJ important) (JJ diagnostic) (JJ prognostic) (NN factor)) (NP (JJ therapeutic) (NN target) (NN breast) (NN cancer)))) |ET| |BS|9:G05.360.340.024.340.375.500 10:A01.236 52:E02 63:G05.360.340.024.340.375.500.791.295.305 263:E01|ES| 18:1 19:1 23:1 24:1 160:1 185:1 541:1 691:1 884:1 901:1 902:1 903:1
1 	|BT| (S (NP (DT A) (JJR better) (NN understanding) (NN mechanism) (NN Cby) (NN gene) (NN activation) (NN LSCC)) (VP (MD could) (VP (VB provide) (NP (JJ potential) (JJ novel) (JJ therapeutic) (NN target) (JJ human) (JJ laryngeal) (NN carcinoma))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 239:F02.463.188.357 259:D12.776.395.240.150.500 264:G05.355.315.800 265:C04.557.470.200 266:E07.695.450 267:A04.329|ES| 9:1 19:1 36:1 69:1 160:1 162:1 225:1 304:1 541:1 711:1 827:1 891:1 904:1 905:1 906:1 907:1 908:1 909:1
1 	|BT| (S (NP (NP (DT A) (JJ functional) (JJ genomic) (NN approach)) (VP (VBG integrating) (NP (NP (NN microarray) (JJ proteomic) (NN analysis)) (VP (VBN done) (NP (NN laboratory)))))) (VP (VBD identified) (NP (JJ 14-3-3zeta) (JJ putative) (NN oncogene)) (WHNP (WHNP (WP$ whose) (NN activation)) (NP (JJ common) (VBN driven) (JJ genomic) (NN amplification) (NN lung) (NN adenocarcinoma))))) |ET| |BS|9:G05.360.340.024.340.375.500 66:F01.658.293 268:H01.158.273.180.350 269:G05.360.340 270:H01.158.201.843 271:N02.278.487|ES| 19:1 24:1 69:1 225:1 255:1 328:1 415:1 623:1 655:1 661:1 910:1 911:1 912:1 913:1 914:1 915:1 916:1 917:1 918:1 919:1 920:1 921:1
1 	|BT| (S (NP (DT A) (NN relationship) (JJ renal) (NN tumor) (NN ASPS)) (ADVP (RB initially)) (VP (VBD suggested) (NP (JJ cytogenetic) (NN finding) (JJ balanced) (-LRB- -LRB-) (NN X) (: ;) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN p11) (NN .2) (: ;)) (NP (CD q25)) (-RRB- -RRB-) (SBAR (S (NP (NP (CD two) (NN case)) (, ,) (NP (NN ASPL-TFE3) (NN fusion) (NN transcript))) (VP (VBD confirmed) (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction))))))) |ET| |BS|272:E05.393.620.500.725 273:H01.158.273.343.180 274:C04.588.945.947.535 275:C23.888|ES| 2:1 7:1 10:1 14:1 19:1 69:1 217:1 223:1 768:1 922:1 923:1 924:1 925:1 926:1 927:1 928:1 929:1 930:1 931:1 932:1 933:1 934:1 935:1 936:1 937:1 938:1 939:1 940:1 941:1
1 	|BT| (NP (NNS Aberrations) (NP (NP (NP (JJ fragile) (NN histidine) (NN triad)) (PRN (-LRB- -LRB-) (NP (NN FHIT)) (-RRB- -RRB-))) (NN gene) (JJ idiopathic) (JJ pulmonary) (NN fibrosis))) |ET| |BS|6:G05.360.340.024.340 276:C08.381.483.487.500 277:D12.125.072.329|ES| 9:1 10:1 14:1 19:1 942:1 943:1 944:1 945:1 946:1 947:1 948:1 949:1
1 	|BT| (S (NP (VBG Activating) (NP (NN alteration) (NN variety) (JJ potential) (JJ oncogenic) (NN driver) (NN gene))) (ADVP (RB also)) (VP (VBD identified) (NP (NP (NNP NSCLC)) (, ,) (PP (VBG including) (NP (NN ROS1))) (, ,) (NP (NNP RET)) (, ,) (NP (NN MET)) (, ,) (NP (NN HER2)) (, ,) (NP (NN BRAF))))) |ET| |BS|18:G05.365.590 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 110:C04.588.894.797.520.109.220.249 278:D08.811.913.696.620.682.700.559.842.374 279:D27.888.569.100|ES| 2:1 5:1 9:1 19:1 188:1 329:1 561:1 623:1 827:1 950:1 951:1 952:1 953:1 954:1 955:1 956:1 957:1 958:1
1 	|BT| (NP (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB examine) (NP (NN status) (NP (NP (JJ clinical) (NN significance) (JJ anaplastic) (NN lymphoma) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN ALK)) (-RRB- -RRB-))) (NN gene) (NP (NP (NN alteration) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN patient)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 104:C04.557.470.200.025.255|ES| 9:1 10:1 14:1 19:1 84:1 104:1 120:1 303:1 304:1 416:1 441:1 470:1 557:1 591:1 828:1 951:1 959:1 960:1 961:1 962:1
1 	|BT| (NP (NP (NN ALK) (NN gene) (NN copy) (NN number)) (NP (NN gain) (JJ clinical) (NN significance) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 280:G05.380.350|ES| 9:1 19:1 84:1 303:1 304:1 557:1 646:1 962:1 963:1 964:1
1 	|BT| (S (NP (DT All) (NN fusion)) (VP (VBD identified) (SBAR (S (NP (NP (NNP RET) (NN KIF5B) (NN gene)) (, ,) (NP (NP (NNP RET) (NN fusion) (NN CCDC6) (NN NCOA4) (NN gene)) (, ,) (NP (JJ characteristic) (NN thyroid) (NN cancer)) (, ,))) (VP (VBD identified) (NP (JJ irradiated) (NN lung) (NN cell))))))) |ET| |BS|6:G05.360.340.024.340 13:D01.339.387 41:A11 182:A04.411 281:E02.815|ES| 2:1 9:1 18:1 19:1 94:1 328:1 336:1 623:1 936:1 956:1 965:1 966:1 967:1 968:1 969:1 970:1
1 	|BT| (NP (NP (NP (NP (JJ Altered) (NN expression) (JJ human) (NN enhancer) (NN filamentation) (CD 1)) (PRN (-LRB- -LRB-) (NP (NP (NN HEF1)) (: ;) (NP (ADJP (RB also) (VBN known)) (NN NEDD9) (NN Cas-L))) (-RRB- -RRB-))) (NP (VBN implicated) (NN progression) (NN melanoma) (, ,) (NN breast) (, ,) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 282:C04.557.465.625.650.510|ES| 2:1 5:1 10:1 14:1 19:1 23:1 36:1 48:1 98:1 115:1 217:1 245:1 556:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1
1 	|BT| (NP (NP (NP (NP (JJ Altered) (NN expression) (JJ human) (NN enhancer) (NN filamentation) (CD 1)) (PRN (-LRB- -LRB-) (NP (NP (NN HEF1)) (: ;) (NP (ADJP (RB also) (VBN known)) (NN NEDD9) (NN Cas-L))) (-RRB- -RRB-))) (NP (VBN implicated) (NN progression) (NN melanoma) (, ,) (NN breast) (, ,) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 15:F01.829.316.616 16:C23.550.291.656 32:C04.697.098.500 33:C04.697.098 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 239:F02.463.188.357 282:C04.557.465.625.650.510|ES| 2:1 5:1 10:1 14:1 19:1 23:1 31:1 36:1 48:1 78:1 98:1 115:1 217:1 245:1 433:1 438:1 556:1 889:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1 979:1
1 	|BT| (FRAG (SBAR (IN Although) (S (NP (NP (NP (JJ additional) (NN study) (NN animal) (NN model)) (VP (VBN needed) (, ,))) (VP (VBG finding) (VP (VBP suggest) (S (VP (VBG targeting) (NP (NN HMGA2))))))) (VP (MD could) (SBAR (S (NP (RB therapeutically) (JJ beneficial) (NN lung) (NN cancer) (NN cancer)) (VP (VBD characterized) (NP (VBN increased) (NN HMGA2) (NN expression))))))))) |ET| |BS|283:D12.776.260.312.937 284:N03.349.380.420 285:E05.598|ES| 2:1 18:1 19:1 46:1 47:1 72:1 107:1 115:1 131:1 328:1 616:1 796:1 908:1 927:1 980:1 981:1 982:1 983:1 984:1 985:1
1 	|BT| (FRAG (SBAR (IN Although) (S (NP (NN CTCF)) (VP (VBD described) (NP (NP (NP (ADJP (RB significantly) (VBN mutated)) (NN gene) (JJ endometrial) (NN cancer) (NN TCGA)) (, ,) (NP (NN A) (-LRB- -LRB-) (CD 7) (-RRB- -RRB-) (NN track))) (SBAR (S (NP (JJ variant) (VBG leading) (NN T204) (NNS frameshifts)) (VP (VBD reported))))))))) |ET| |BS|6:G05.360.340.024.340 86:D01.268.556.435 286:C04.588.945.418.948.585 287:G05.365.590.265|ES| 2:1 9:1 10:1 14:1 18:1 19:1 69:1 107:1 124:1 229:1 276:1 634:1 639:1 986:1 987:1 988:1 989:1 990:1 991:1 992:1 993:1
1 	|BT| (S (SBAR (IN Although) (S (NP (NP (NN therapy)) (VP (VBG targeting) (NP (JJ high) (NN EphA1) (NN expression)))) (VP (VBP seem) (NP (JJ plausible) (NN CRC))))) (, ,) (S (NP (NN loss) (NN expression)) (VP (VBD advanced) (NP (NN disease)))) (VP (VBZ suggests) (SBAR (S (NP (NP (NP (JJ potential) (NN risk)) (VBN targeted) (NN therapy)) (, ,) (VP (VBG selecting) (NP (NN loss) (NN expression))) (, ,)) (VP (MD might) (VP (VB contribute) (NP (NN disease) (NN progression)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 61:E05.318.740.600.800 288:C23.550.288|ES| 2:1 16:1 19:1 32:1 48:1 107:1 115:1 130:1 171:1 178:1 245:1 331:1 450:1 616:1 798:1 827:1 994:1 995:1 996:1 997:1 998:1 999:1
1 	|BT| (S (PP (IN Among) (NP (ADJP (RB frequently) (VBN deleted)) (JJ chromosomal) (NN site))) (, ,) (NP (NN LOH) (NN chromosome) (NN 3p)) (VP (VBD detected) (NP (NN MM)) (, ,) (S (VP (VBG suggesting) (S (NP (NN presence)) (NP (CD one) (NP (JJ several) (NN tumour) (NN suppressor) (NN gene) (JJ important) (NN role)) (NN development) (NN disease))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 206:G05.360.340.024.340.375.249 289:A11.284.187 290:G05.365.590.029.530 291:F03.625.421|ES| 2:1 9:1 19:1 31:1 35:1 262:1 346:1 698:1 700:1 902:1 998:1 1000:1 1001:1 1002:1 1003:1 1004:1 1005:1 1006:1 1007:1 1008:1 1009:1 1010:1 1011:1
1 	|BT| (S (NP (NN Amplification) (NN over-expression) (NN MAP3K3) (NN gene) (JJ human) (NN breast) (NN cancer)) (VP (VBZ promotes) (NP (NN formation) (NN survival) (NN breast) (NN cancer) (NN cell)))) |ET| |BS|20:G03.495 55:B01.050.150.900.649.801.400.112.400.400 108:G04.299.316 155:G05.355.310|ES| 9:1 18:1 19:1 23:1 36:1 43:1 94:1 274:1 298:1 1012:1 1013:1 1014:1
1 	|BT| (S (NP (DT An) (JJ integrative) (NN bioinformatics) (NN analysis) (NN region)) (VP (VBN nominated) (NP (NN MAP3K3) (NN gene) (JJ potential) (JJ therapeutic) (NN target) (NN breast) (NN cancer)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 10:A01.236 12:Z01.542.049 52:E02 240:H01.158.273.180 292:Z01|ES| 9:1 18:1 19:1 23:1 160:1 541:1 661:1 667:1 827:1 830:1 1014:1 1015:1 1016:1 1017:1
1 	|BT| (S (NP (NN Analysis) (NN TP53) (NN CTNNB1) (NN gene) (NN mutation)) (NP (NNP HG) (NN component) (NNS MASCs)) (ADVP (RB well)) (NP (NN detection) (NN copy) (NN number) (NN aberration) (NN EGFR) (NN CCND1) (NN gene)) (VP (VBP harbor) (NP (NN abnormality)))) |ET| |BS|6:G05.360.340.024.340 18:G05.365.590 23:D12.776.091.249 254:C16.131 293:D01.268.556.504 294:G05.360.340.024.340.137|ES| 9:1 19:1 34:1 119:1 187:1 646:1 787:1 963:1 1018:1 1019:1 1020:1 1021:1 1022:1 1023:1 1024:1 1025:1 1026:1 1027:1
